Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

Seltzer, Vicki; Vogl, Steven E.; Kaplan, Barry H.

doi:10.1016/0090-8258(85)90249-5

Cited by 74 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…favourable to those previously reported by Markman et al (1991), and others (Seltzer et al, 1985;Gershenson et al, 1989;Kavanagh and Nicaise, 1989;Kjorstad et al, 1992), using reinduction therapy with 3-or 4-weekly intervals. Of note, cisplatin at a dose of 70 mg m 72 weekly six times in a period of 8 weeks, compared with the standard dose of 75 mg m 72 every 3 weeks results in a 2.1-fold higher scheduleintensity.…”

Section: Clinicalsupporting

confidence: 68%

“…Multiple studies have shown that the time interval between the completion of first-line chemotherapy and the relapse is the most important prognostic factor in the likelihood of responding to second-line therapy (Seltzer et al, 1985;Gershenson et al, 1989;Kavanagh and Nicaise, 1989;Markman et al, 1991;Kjorstad et al, 1992;Berek et al, 1998). This impact accounts not only for the successful reinduction rate to platinum but also for the response rate to other active agents, including the taxanes, topotecan, gemcitabine and anthracyclins (de Wit et al, 1994;Eisenhauer et al, 1994;Lund et al, 1994;Kavanagh et al, 1996;Muggia et al, 1997;ten Bokkel Huinink et al, 1997;Rose et al, 1998).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

et al. 2002

View full text Add to dashboard Cite

We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory ovarium cancer. One hundred and seven patients were entered on the study, 98 patients completed the induction therapy consisting of cisplatin at either 50 or 70 mg m 72 weekly for six administrations plus oral etoposide at a dose of 50 mg daily. Of these 98 patients, 38 had a platinum treatment-free interval of more than 12 months, 32 had an interval between 4 and 12 months, and 28 had progressed during or within 4 months after last platinum therapy. We assessed response rates and time to progression, and also response duration and survival. Analyses were done on the 98 evaluable patients. All 107 patients were considered evaluable for toxicity. Of the 38 patients with a treatment-free interval of more than 12 months, 92% responded, with 63% complete responses. The median progression-free survival in these patients was 14 months, and the median survival was 26 months. Of the 32 patients with an interval of 4 -12 months, 91% responded, with 31% complete responses, a median progression-free interval of 8 and a median overall survival of 16 months. Of the 28 patients with platinum-refractory disease, 46% as yet responded, with 29% complete responses, median progression-free interval of 5 and an overall survival of 13 months. Haematologic and non-haematologic, particularly renal toxicity and neurotoxicity, were notably mild. We conclude that this intensive regimen of weekly cisplatin plus daily etoposide is highly effective and well tolerated in patients with ovarian cancer relapsing after conventional platinum-based combination chemotherapy, including patients who have progressed during or within 4 months after platinum treatment.

show abstract

Section: Clinicalsupporting

confidence: 68%

mentioning

confidence: 99%

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The cycle was repeated every 28 days. The mean number of courses administered was 7 (range, [3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Each patient had a CA125 and a complete blood count obtained, as well as a comprehensive physical examination before each cycle.…”

Section: Methodsmentioning

confidence: 99%

“…2 Response rates of 33% to 100% have been reported in patients with chemosensitive disease who have been retreated with a platinum compound and/or taxanes. [3][4][5][6] Unfortunately, for those individuals with chemoresistant recurrent disease, the probability of response to second-line therapy is small. Although a number of treatment options exist including a list of cytotoxic agents given intravenously and in some cases intraperitoneally, the costs, side effects of the therapy, and the patient's overall quality of life needs to be weighted against the probability of response.…”

mentioning

confidence: 99%

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Davis-Perry¹,

Hernández²,

Houck³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this study was to determine the response to melphalan in patients with recurrent epithelial ovarian cancer after platinum-based therapy. This retrospective observational study analyzed 10 patients with recurrent epithelial ovarian carcinoma treated with melphalan between August 1995 and April 2001. All had received primary platinum-based therapy. Nine of the 10 patients had chemosensitive disease. All but one patient had received one or more second-line therapies prior to melphalan. The median time to recurrence after first-line therapy was 26 months (range, 3-68). Treatment with melphalan resulted in 2 (20%) complete responses and 1 (10%) partial response (response rate, 30%; 95% CI 8%, 65%). The median progression-free interval after initiation of melphalan therapy was 8 months (range, 3-23). The most common side effects were grade I thrombocytopenia (20% of courses) and grade II leukopenia (18% of courses). The use of melphalan as palliative chemotherapy in patients with recurrent ovarian cancer results in response rates similar to those reported with other more expensive agents. Melphalan at the doses reported here has a favorable toxicity profile.

show abstract

“…Although up to 80% of cases achieve an objective response with platinum-containing regimens, about 22% of patients progress while receiving initial platinum-based treatment and are defined refractory to chemotherapy (Kavanagh et al, 1995), 40% of patients generally relapse or progress within 12 months and 20% after 12 months from the end of first-line chemotherapy (Ozols and Young, 1991;Thigpen, 1999). The probability of a second response increases with the relapse-free period (Seltzer et al, 1985;Gore et al, 1990;Markman et al, 1991;Weiss et al, 1991;Zanaboni et al, 1991;Eisenhauer et al, 1997;Cantù et al, 2002).…”

mentioning

confidence: 99%

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group

et al. 2004

View full text Add to dashboard Cite

Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

Cited by 74 publications

References 11 publications

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Contact Info

Product

Resources

About